Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy

Study Overview
=================
Brief Summary
-----------------
To compare the short-term effect of intravitreal aflibercept injection between two subtypes of polypoidal choroidal vasculopathy

Detailed Description
-----------------
The subjects were classified into two subtypes (type 1 and type 2 polypoidal choroidal vasculopathy) based on the presence or the absence of both of a feeder and a draining vessels on indocyanine green angiography. All received intravitreal injection of aflibercept (2.0 mg) at baseline and months 1, 2 and 4.

Conditions
-----------------
Polypoidal Choroidal Vasculopathy

Intervention / Treatment
-----------------
* Drug: Aflibercept
* Drug: Indocyanine green angiography (intraveonus indocyanine green dye)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptomatic typical PCV accompanying branch vascular network involving subfoveal area signed informed consent; and over 6 months follow-up period after enrollment. Exclusion Criteria: retinal diseases other than PCV extrafoveal PCV not involving subfoveal area massive subretinal hemorrhage blocking polypoidal lesion on ICGA severe media opacity such as senile cataract previous history of intravitreal injection previous intraocular surgery history except cataract surgery which was done more than 3 months.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Type 1 polypoidal choroidal vasculopathy<br>Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate. | Drug: Aflibercept<br>* Total 4 times of intravitreal aflibercept injection was performed<br>* Other names: Eylea;Drug: Indocyanine green angiography (intraveonus indocyanine green dye)<br>* At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.<br>|
| Type 2 polypoidal choroidal vasculopathy<br>Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate. | Drug: Aflibercept<br>* Total 4 times of intravitreal aflibercept injection was performed<br>* Other names: Eylea;Drug: Indocyanine green angiography (intraveonus indocyanine green dye)<br>* At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Regression Rate of Polyp on Indocyanine Green Angiography | Indocyanine green angiography performed initially and at 3 months were used to determine the polyp regression. The definition of complete polyp regression is that the polyps at initial visit disappeared at 3 months on indocyanine green angiography. The partial regression means the polyps remain, but the size decreased >30%. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best Corrected Visual Acuity | Best corrected visual acuity assessed at baseline, 3 months, and 6 months | baseline, 3 months, and 6 monthsc |